TrialBlood2022

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.

Mahmoud Elsawy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.